sotorasib
AXP000023.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS
- Originator
- Amgen
- Sponsor
- Amgen
Names
| Name | Type | Source |
|---|---|---|
| sotorasib | preferred name, INN | curator, ncit |
| Lumakras | brand | fda |
| Lumykras | brand | press |
| AMG 510 | code | ncit |
Cross-references
- NCI Thesaurus
- C154287
- Wikidata
- Q75175937
- FDA UNII
- 2B2VM6UC8G
Approvals
No regulatory approval recorded.
Clinical trials (71)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07874737 | Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia | Not yet recruiting | Phase 2 | 2026-12 | 2028-12 | 20 | Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) |
| NCT07543172 | CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer | Not yet recruiting | Phase 2 | 2026-10-15 | 2029-06-01 | 29 | Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 |
| NCT07012031 | Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | Recruiting | Phase 1/2 | 2026-06-17 | 2027-06-14 | 37 | Locally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 |
| NCT07318389 | ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | Recruiting | Early phase 1 | 2026-04-22 | 2027-11-14 | 100 | Dynamic Tumor Resistance; Metastatic Colorectal Cancer |
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212 | Recruiting | Phase 1/2 | 2026-03-27 | 2029-09 | 229 | Mesothelioma; NSCLC (Advanced Non-small Cell Lung Cancer); Pancreatic Cancer |
| NCT07172919 | A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation | Recruiting | Phase 2 | 2026-01-02 | 2028-07-01 | 14 | Advanced Solid Tumors |
| NCT07124884 | 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab | Not yet recruiting | Phase 2 | 2025-08-31 | 2030-06-30 | 300 | Colorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer |
| NCT07143513 | Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients | Completed | 2025-08-11 | 2025-12-07 | 102 | Non-Small Cell Lung Cancer | |
| NCT06892054 | Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma | Recruiting | Phase 1 | 2025-08-08 | 2030-08-08 | 15 | Pancreatic Adenocarcinoma |
| NCT06068153 | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC | Withdrawn | Phase 2 | 2025-03 | 2026-09-30 | 0 | KRAS G12C; Metastatic Non Small Cell Lung Cancer |
| NCT06804824 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | Recruiting | Phase 1 | 2025-02-25 | 2027-08-01 | 220 | Advanced Solid Tumors |
| NCT06807619 | A Study of Sotorasib in People With Brain Tumors | Recruiting | Phase 1 | 2025-01-29 | 2028-01 | 16 | Brain Tumor |
| NCT06659341 | A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation | Recruiting | Phase 1 | 2024-11-08 | 2027-11-30 | 104 | Advanced Solid Tumors Harboring KRAS G12C Mutation |
| NCT06497556 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | Active not recruiting | Phase 3 | 2024-09-23 | 2026-05-19 | 338 | KRAS G12C Lung Cancer; Non-Small Cell Lung Cancer |
| NCT06333951 | Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | Active not recruiting | Phase 1 | 2024-09-17 | 2026-10-31 | 49 | Non-small Cell Lung Cancer; Thoracic Tumors |
| NCT06582771 | A Study of Sotorasib in People With Non-Small Cell Lung Cancer | Recruiting | Phase 2 | 2024-08-30 | 2027-08 | 39 | Non Small Lung Cancer |
| NCT06532149 | ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer | Unknown | 2024-08-05 | 2026-09-05 | 80 | Erectile Dysfunction; Hypogonadism, Male; NSCLC Stage IV; Sex Disorder | |
| NCT05638295 | Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | Active not recruiting | Phase 2 | 2024-08-01 | 2028-12-31 | 105 | Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | Recruiting | Phase 3 | 2024-07-17 | 2028-09-25 | 450 | Metastatic Colorectal Cancer |
| NCT06061523 | A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants | Withdrawn | Phase 1 | 2024-07-15 | 2024-09-09 | 0 | Healthy Participants |
| NCT06249282 | Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting | Phase 1 | 2024-04-24 | 2026-11-24 | 15 | Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 |
| NCT05815186 | Ladarixin With Sotorasib in Advanced NSCLC - Phase II | Withdrawn | Phase 2 | 2024-04 | 2025-04 | 0 | Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation |
| NCT06333678 | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) | Terminated | Phase 2 | 2024-03-20 | 2026-01-27 | 10 | Non-Small Cell Lung Cancer |
| NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Recruiting | Phase 3 | 2023-11-16 | 2027-06-30 | 750 | Non-Small Cell Lung Cancer (NSCLC) |
| NCT06314763 | Rivaroxaban Sotorasib Interaction Study | Completed | Phase 4 | 2023-11-09 | 2024-03-21 | 21 | Drug Drug Interaction Study |
| NCT06127940 | K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation | Unknown | Phase 1 | 2023-10-15 | 2025-06-01 | 20 | Non-small Cell Lung Cancer Metastatic |
| NCT05815173 | Ladarixin With Sotorasib in Advanced NSCLC | Recruiting | Phase 1 | 2023-08-01 | 2027-08 | 40 | Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation |
| NCT05993455 | A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab | Unknown | Phase 2 | 2023-07-03 | 2023-09-04 | 24 | Efficacy |
| NCT05845450 | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | Recruiting | Phase 2 | 2023-05-11 | 2027-05 | 197 | Colorectal Cancer; Resectable Colorectal Carcinoma |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | Phase 2 | 2023-04-07 | 2030-07-01 | 2900 | Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm |
| NCT05631249 | Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | Recruiting | Phase 2 | 2022-12-13 | 2027-12-12 | 40 | KRAS P.G12C; Non Small Cell Lung Cancer |
| NCT05374538 | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | Terminated | Phase 1 | 2022-11-09 | 2023-08-26 | 3 | Non-small Cell Lung Cancer |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | Withdrawn | Phase 1/2 | 2022-09-13 | 2023-01-31 | 0 | KRAS P.G12C; Metastatic Pancreatic Cancer; Pancreatic Cancer; Unresectable Pancreatic Cancer |
| NCT05451056 | An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib | Unknown | Phase 2 | 2022-08-01 | 2026-01 | 37 | Non Small Cell Lung Cancer |
| NCT05497557 | A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers | Completed | Phase 1 | 2022-07-14 | 2022-09-08 | 16 | Healthy Volunteers |
| NCT05400577 | Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC | Withdrawn | Phase 2 | 2022-07-13 | 2024-01-01 | 0 | Non-Small Cell Lung Cancer |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | Terminated | Phase 1 | 2022-07-06 | 2024-08-22 | 28 | Metastatic NSCLC; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Solid Tumor, Adult |
| NCT05180422 | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | Withdrawn | Phase 1/2 | 2022-06-15 | 2023-01-31 | 0 | Non Small Cell Lung Cancer |
| NCT05311709 | Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities | Unknown | Phase 2 | 2022-05-30 | 2024-10-01 | 100 | Cancer; Cancer, Lung; Lung Cancer; Lung Cancer Stage IV; Mutation; NSCLC Stage IV; NSCLC, Stage III |
| NCT05198934 | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | Completed | Phase 3 | 2022-04-19 | 2025-07-16 | 160 | Colorectal Cancer (CRC) |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | Active not recruiting | Phase 1/2 | 2022-04-12 | 2026-06 | 153 | KRAS Activating Mutation; Non Small Cell Lung Cancer |
| NCT05118854 | A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation | Active not recruiting | Phase 2 | 2022-03-30 | 2027-10-20 | 13 | Lung Cancer |
| NCT05398094 | Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy | Recruiting | Phase 2 | 2022-03-21 | 2027-12-31 | 19 | KRAS P.G12C; Non-small Cell Lung Cancer Stage III |
| NCT05327491 | A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets | Completed | Phase 1 | 2022-03-21 | 2022-07-17 | 146 | Healthy Participants |
| NCT05313009 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | Terminated | Phase 1/2 | 2022-03-07 | 2023-07-07 | 5 | Non-Small Cell Lung Cancer |
| NCT05273047 | RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC | Unknown | 2022-03-01 | 2023-08-30 | 458 | KRAS P.G12C; Nsclc | |
| NCT04933695 | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment | Terminated | Phase 2 | 2022-01-28 | 2025-05-28 | 42 | Non-small Cell Lung Cancer |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Completed | Phase 2 | 2021-12-30 | 2024-07-03 | 47 | Non-Small Cell Lung Cancer |
| NCT05036291 | A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors | Terminated | Phase 1 | 2021-10-01 | 2025-09-24 | 25 | Advanced Solid Tumor |
| NCT04959981 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | Completed | Phase 1 | 2021-09-02 | 2023-04-27 | 24 | Advanced Non-squamous Non-small-cell Lung Cancer |
| NCT05045638 | Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants | Completed | Phase 1 | 2021-08-20 | 2021-10-10 | 13 | Healthy Participants |
| NCT05048784 | A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants | Completed | Phase 1 | 2021-08-16 | 2022-02-18 | 145 | Healthy Participants |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | Terminated | Phase 1 | 2021-06-15 | 2026-03-30 | 91 | Advanced Solid Tumor; Metastatic Solid Tumor; Non-Small Cell Lung Cancer |
| NCT04887064 | Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment | Completed | Phase 1 | 2021-04-22 | 2022-03-09 | 20 | Hepatic Impairment |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | Active not recruiting | Phase 2 | 2021-04-16 | 2026-12-31 | 116 | Lung Adenocarcinoma; Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
| NCT04720976 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | Completed | Phase 1/2 | 2021-03-23 | 2023-12-19 | 58 | NSCLC; Solid Tumor |
| NCT05599828 | A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants | Completed | Phase 1 | 2020-07-17 | 2020-09-13 | 14 | Healthy Participants |
| NCT04303780 | Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). | Completed | Phase 3 | 2020-06-04 | 2022-08-02 | 345 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC |
| NCT04380753 | AMG 510 Ethnic Sensitivity Study (CodeBreaK 105). | Completed | Phase 1 | 2020-04-28 | 2021-12-31 | 12 | Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation |
| NCT05578859 | A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects | Completed | Phase 1 | 2020-03-11 | 2020-03-24 | 8 | Healthy Subjects |
| NCT05571163 | A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants | Completed | Phase 1 | 2020-03-06 | 2020-06-14 | 13 | Healthy Participants |
| NCT05581992 | Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants | Completed | Phase 1 | 2020-01-06 | 2020-01-26 | 14 | Healthy Participants |
| NCT04185883 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Active not recruiting | Phase 1 | 2019-12-17 | 2026-12-17 | 610 | Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation |
| NCT05568082 | A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants | Completed | Phase 1 | 2019-12-03 | 2019-12-17 | 14 | Healthy Participants |
| NCT05581758 | A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants | Completed | Phase 1 | 2019-11-14 | 2019-11-25 | 14 | Healthy Participants |
| NCT05550129 | Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants | Completed | Phase 1 | 2019-11-13 | 2019-11-25 | 13 | Healthy Volunteers |
| NCT05598281 | Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants | Completed | Phase 1 | 2019-11-05 | 2019-11-19 | 14 | Healthy Participants |
| NCT05577624 | A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants | Completed | Phase 1 | 2019-11-05 | 2019-12-01 | 14 | Healthy Participants |
| NCT04092673 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | Unknown | Phase 1/2 | 2019-10-25 | 2024-12-31 | 30 | Solid Tumor, Adult |
| NCT03600883 | A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | Completed | Phase 1/2 | 2018-08-27 | 2026-05-29 | 713 | KRAS p.G12C Mutant Advanced Solid Tumors |
| NCT04667234 | Expanded Access of Sotorasib | No longer available | Locally Advanced Metastatic NSCLC; Locally Advanced Unresectable NSCLC; Non Small-cell Lung Cancer |
Recent changes
| Seen | Trial | Change | Detail | Title |
|---|---|---|---|---|
| 2026-11-12 | NCT06659341 | completion slipped | 2027-04-26 → 2027-11-30 | A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation |
| 2026-11-12 | NCT07874737 | new trial | Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia |
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40353648 | Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma. | Journal of chemotherapy (Florence, Italy) | 2026 | name in title: sotorasib |
| PMID 41539179 | Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan. | European journal of cancer (Oxford, England : 1990) | 2026 | name in abstract: sotorasib |
| PMID 41552958 | No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects. | International journal of cancer | 2026 | cited by trial NCT06314763 |
| PMID 41811505 | Clinically actionable molecular alterations in Rb-retained small cell lung carcinoma variants. | Virchows Archiv : an international journal of pathology | 2026 | name in abstract: sotorasib |
| PMID 41907639 | Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report. | Frontiers in oncology | 2026 | name in title: sotorasib |
| PMID 41963020 | A 71-Year-Old Woman With Dyspnea and Hypoxemia After Liver Metastases Cryoablation. | Chest | 2026 | name in abstract: sotorasib |
| PMID 42069451 | Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trial. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2026 | name in title: sotorasib |
| PMID 42173791 | Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer. | Clinical colorectal cancer | 2026 | name in title: sotorasib |
| PMID 42293289 | Lung Adenocarcinoma Developing Pleomorphic Carcinoma With ERBB3 Amplification After Acquired Resistance to Sotorasib: A Case Report. | JTO clinical and research reports | 2026 | name in title: sotorasib |
| PMID 42405535 | Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report. | The oncologist | 2026 | name in title: sotorasib |
| PMID 42428178 | Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy. | Cureus | 2026 | name in title: sotorasib |
| PMID 42474245 | First report of dual KRAS Y96C/Y96S resistance mutations detected by liquid biopsy in KRAS G12C-mutant metastatic colorectal cancer. | The oncologist | 2026 | name in abstract: sotorasib |
| PMID 42523592 | Transformation from lung adenocarcinoma to pulmonary giant cell carcinoma following targeted therapy: a case report. | Frontiers in oncology | 2026 | name in abstract: sotorasib |
| PMID 42617424 | Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study. | ESMO open | 2026 | name in title: sotorasib |
| PMID 42630346 | Pulmonary carcinoid harboring a KRAS G12C mutation identified through comprehensive genomic profiling and responding to sotorasib: A case report. | Rare tumors | 2026 | name in title: sotorasib |
| PMID 42756523 | Response to Sotorasib in a patient with recurrent KRAS G12C-mutated low-grade serous ovarian cancer: a case report and literature review. | Gynecologic oncology reports | 2026 | name in title: sotorasib |
| PMID 42814800 | FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer. | Science translational medicine | 2026 | cited by trial NCT05074810 |
| PMID 42891951 | Dose-Dependent Intracranial Response to Sotorasib in KRASG12C-Mutated Lung Cancer Brain Metastases: A Case Report. | Oncology research and treatment | 2026 | name in title: sotorasib |
| PMID 42929675 | Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. | The New England journal of medicine | 2026 | cited by trial NCT06497556 |
| PMID 42972108 | Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial. | Nature medicine | 2026 | cited by trial NCT05845450 |
| PMID 39230186 | Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration. | Clinical pharmacology in drug development | 2025 | name in title: sotorasib |
| PMID 39231674 | First Reported Case of Pure Red Cell Aplasia Related to Sotorasib. | Internal medicine (Tokyo, Japan) | 2025 | name in title: sotorasib |
| PMID 39604046 | Impact of Acid-Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic Beverage. | Clinical pharmacology in drug development | 2025 | cited by trial NCT05497557 |
| PMID 39752885 | Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | cited by trial NCT06252649 |
| PMID 39777405 | Impact of Sotorasib, a KRAS G12C Inhibitor, on the Pharmacokinetics and Therapeutic Window of Digoxin, a P-Glycoprotein Substrate. | Clinical pharmacology in drug development | 2025 | cited by trial NCT05598281 |
| PMID 39828218 | A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET). | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2025 | name in title: sotorasib |
| PMID 39970524 | Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study. | European journal of cancer (Oxford, England : 1990) | 2025 | name in title: sotorasib |
| PMID 40110764 | Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report. | The oncologist | 2025 | name in title: sotorasib |
| PMID 40215429 | Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | name in title: sotorasib |
| PMID 40277845 | Successful Management of Acquired von Willebrand Syndrome Associated with Monoclonal Gammopathy of Undetermined Significance After Sotorasib Treatment in a Patient with Non-Small-Cell Lung Carcinoma. | Hematology reports | 2025 | name in title: sotorasib |
| PMID 40333694 | JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | cited by trial NCT04720976 |
| PMID 40542959 | Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation. | Advances in therapy | 2025 | name in title: sotorasib |
| PMID 40774040 | Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. | Lung cancer (Amsterdam, Netherlands) | 2025 | name in title: sotorasib |
| PMID 40812325 | Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. | The Lancet. Oncology | 2025 | name in title: sotorasib |
| PMID 40831448 | Clinical Impact of Hepatic Impairment on the Pharmacokinetics of Sotorasib and Its Major Metabolites: Implications for Dose Adjustment. | Journal of clinical pharmacology | 2025 | name in title: sotorasib |
| PMID 40866105 | Sotorasib provides a durable response in high-grade metastatic ovarian serous adenocarcinoma harbouring KRAS G12C mutation. | BMJ case reports | 2025 | name in title: sotorasib |
| PMID 41114813 | Diffuse Large B-cell lymphoma in a Ras-Associated Autoimmune Leukoproliferative Disorder (RALD). | Annals of hematology | 2025 | name in abstract: sotorasib |
| PMID 41355935 | Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation. | Case reports in oncological medicine | 2025 | name in abstract: sotorasib |
| PMID 41410376 | Marked Reduction in Tacrolimus and Everolimus Blood Levels Associated With Sotorasib: A Critical Drug Interaction in a Kidney Transplant Recipient. | Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation | 2025 | name in title: sotorasib |
| PMID 38177853 | Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. | Nature medicine | 2024 | name in title: sotorasib |
| PMID 38269310 | Drug-induced lung injury in a patient treated with prior atezolizumab and subsequent sotorasib: A case report. | Respirology case reports | 2024 | name in title: sotorasib |
| PMID 38299192 | The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report. | JTO clinical and research reports | 2024 | name in title: sotorasib |
| PMID 38377774 | Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany. | European journal of cancer (Oxford, England : 1990) | 2024 | name in title: sotorasib |
| PMID 38421129 | Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib. | Clinical pharmacology in drug development | 2024 | name in title: sotorasib |
| PMID 38451823 | Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer. | Anti-cancer drugs | 2024 | name in title: sotorasib |
| PMID 38550295 | Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRASG12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report. | JTO clinical and research reports | 2024 | name in title: sotorasib |
| PMID 38614068 | Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal. | Lung cancer (Amsterdam, Netherlands) | 2024 | name in title: sotorasib |
| PMID 38615940 | Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024 | name in title: sotorasib |
| PMID 38711902 | Sotorasib as first-line therapy in patients with advanced non-small cell lung cancer with KRAS gene mutations combined with brain metastases: a case report. | AME case reports | 2024 | name in title: sotorasib |
| PMID 38799516 | Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report. | Clinical case reports | 2024 | name in title: sotorasib |
| PMID 38917307 | Sotorasib as Fourth-Line Treatment in Pancreatic Cancer: A Case Report and Literature Review. | Rhode Island medical journal (2013) | 2024 | name in title: sotorasib |
| PMID 39016337 | Impact of a High-Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor. | Clinical pharmacology in drug development | 2024 | name in title: sotorasib |
| PMID 39016668 | A case of hepatoid adenocarcinoma of the lung harboring KRAS G12C responded favorably to sotorasib. | Pathology international | 2024 | name in title: sotorasib |
| PMID 39018528 | Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation. | The New England journal of medicine | 2024 | name in title: sotorasib |
| PMID 39029295 | Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC. | European journal of cancer (Oxford, England : 1990) | 2024 | name in title: sotorasib |
| PMID 39074423 | Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study. | Lung cancer (Amsterdam, Netherlands) | 2024 | name in abstract: sotorasib |
| PMID 39247747 | Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report. | World journal of clinical cases | 2024 | name in title: sotorasib |
| PMID 39303400 | Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. | Lung cancer (Amsterdam, Netherlands) | 2024 | name in title: sotorasib |
| PMID 39470877 | Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving Sotorasib. | Advances in therapy | 2024 | name in title: sotorasib |
| PMID 39474565 | Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases. | Case reports in oncology | 2024 | name in title: sotorasib |
| PMID 36546651 | Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. | The New England journal of medicine | 2023 | cited by trial NCT03600883 |
| PMID 36619890 | Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report. | JTO clinical and research reports | 2023 | name in title: sotorasib |
| PMID 36764316 | Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. | Lancet (London, England) | 2023 | cited by trial NCT04303780 |
| PMID 36841727 | A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. | Clinical lung cancer | 2023 | name in abstract: sotorasib |
| PMID 37008835 | Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report. | Case reports in oncology | 2023 | name in title: sotorasib |
| PMID 37098232 | Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | name in title: sotorasib |
| PMID 37131995 | De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report. | JTO clinical and research reports | 2023 | name in title: sotorasib |
| PMID 37217096 | Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023 | name in title: sotorasib |
| PMID 37384866 | Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer. | JCO precision oncology | 2023 | name in title: sotorasib |
| PMID 37408855 | Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report. | Drug target insights | 2023 | name in title: sotorasib |
| PMID 37870968 | Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. | The New England journal of medicine | 2023 | name in title: sotorasib |
| PMID 37886215 | Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report. | Respiratory medicine case reports | 2023 | name in title: sotorasib |
| PMID 38044989 | Case Report: Case series: association between blood concentration and side effects of sotorasib. | Frontiers in oncology | 2023 | name in title: sotorasib |
| PMID 38096473 | Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases. | JCO precision oncology | 2023 | name in title: sotorasib |
| PMID 34919824 | Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. | The Lancet. Oncology | 2022 | name in title: sotorasib |
| PMID 35643747 | Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report. | Clinical lung cancer | 2022 | name in title: sotorasib |
| PMID 35735665 | The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC). | Clinics and practice | 2022 | name in abstract: sotorasib |
| PMID 36157699 | Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. | Case reports in oncology | 2022 | name in title: sotorasib |
| PMID 36353445 | Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants. | 3 Biotech | 2022 | name in abstract: sotorasib |
| PMID 36388799 | Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report. | Annals of translational medicine | 2022 | name in title: sotorasib |
| PMID 36471683 | Remarkable Intracranial Response to Sotorasib in a Patient With KRAS G12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report. | JTO clinical and research reports | 2022 | name in title: sotorasib |
| PMID 34096690 | Sotorasib for Lung Cancers with KRAS p.G12C Mutation. | The New England journal of medicine | 2021 | name in title: sotorasib |
| PMID 34590053 | Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report. | JTO clinical and research reports | 2021 | name in title: sotorasib |
| PMID 31820981 | Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors. | Journal of medicinal chemistry | 2020 | cited by trial NCT03600883 |
| PMID 32955176 | KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. | The New England journal of medicine | 2020 | name in title: sotorasib |
| PMID 31666701 | The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. | Nature | 2019 | name in title: AMG 510 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40770093 | NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. | Nature | 2026 | name in abstract: sotorasib |
| PMID 40776650 | Bioinformatics And Experimental Insights Into Sotorasib Resistance Mechanisms in Non-small-cell Lung Cancer. | Anti-cancer agents in medicinal chemistry | 2026 | name in title: sotorasib |
| PMID 40971231 | Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future. | CA: a cancer journal for clinicians | 2026 | name in abstract: sotorasib |
| PMID 40991960 | Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer. | Annual review of medicine | 2026 | name in abstract: sotorasib |
| PMID 41165466 | Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. | Cancer research | 2026 | name in abstract: sotorasib |
| PMID 41191614 | A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development. | Anti-cancer drugs | 2026 | name in abstract: sotorasib |
| PMID 41340466 | Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. | Molecular cancer therapeutics | 2026 | name in abstract: sotorasib |
| PMID 41348990 | Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | name in title: sotorasib |
| PMID 41380450 | Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives. | Bioorganic chemistry | 2026 | name in abstract: sotorasib |
| PMID 41396253 | Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review. | American journal of clinical oncology | 2026 | name in abstract: sotorasib |
| PMID 41419408 | Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights. | Hepatobiliary & pancreatic diseases international : HBPD INT | 2026 | name in abstract: sotorasib |
| PMID 41475546 | ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. | The Journal of biological chemistry | 2026 | name in title: sotorasib |
| PMID 41492050 | Development and Validation of the Novel, Fast Bioanalytical LC-MS/MS Technique for the Simultaneous Estimation of Sotorasib and Ondansetron: Application to In Vivo Pharmacokinetic Assessments. | Biomedical chromatography : BMC | 2026 | name in title: sotorasib |
| PMID 41508946 | Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review). | Oncology reports | 2026 | name in abstract: sotorasib |
| PMID 41526435 | KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors. | NPJ precision oncology | 2026 | name in abstract: sotorasib |
| PMID 41529383 | Advances on drug therapy for KRASG12C-mutant non-small-cell lung cancer. | Translational oncology | 2026 | name in abstract: sotorasib |
| PMID 41581311 | Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC. | Lung cancer (Amsterdam, Netherlands) | 2026 | name in abstract: sotorasib |
| PMID 41585660 | Environmental Pollutants and Protein Destabilization in Lung Cancer: Anticancer Drug Strategies for Structural Stability. | ACS omega | 2026 | name in abstract: sotorasib |
| PMID 41638869 | Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. | Journal for immunotherapy of cancer | 2026 | name in title: sotorasib |
| PMID 41652638 | NRAS and SREBF1 identified as mitophagy-associated risk genes for rheumatoid arthritis through interpretable machine learning and experimental validation studies. | BMC rheumatology | 2026 | name in abstract: sotorasib |
| PMID 41654096 | Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis. | Critical reviews in oncology/hematology | 2026 | name in abstract: sotorasib |
| PMID 41654234 | Synthesis and characterization of bicyclo[1.1.0]butane amides and 5-methylene-3-azabicyclo[5.1.0]octan-4-ones as covalent modifiers. | Bioorganic & medicinal chemistry letters | 2026 | name in abstract: sotorasib |
| PMID 41663526 | Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases. | Cancer gene therapy | 2026 | name in abstract: sotorasib |
| PMID 41665865 | Evaluating Post-Progression Survival in the Context of Progression-Free Survival Benefits: A Revisit of the CodeBreaK200 Design. | Therapeutic innovation & regulatory science | 2026 | name in abstract: sotorasib |
| PMID 41670818 | Genomic alterations and their correlation with metabolic-related genes in lung cancer. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2026 | name in abstract: sotorasib |
| PMID 41671906 | Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system. | Lung cancer (Amsterdam, Netherlands) | 2026 | name in title: sotorasib |
| PMID 41697749 | Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models. | The Journal of clinical investigation | 2026 | name in abstract: sotorasib |
| PMID 41697929 | KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future Directions. | Oncology research and treatment | 2026 | name in abstract: sotorasib |
| PMID 41784211 | A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science. | Cancer investigation | 2026 | name in abstract: sotorasib |
| PMID 41786688 | Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells. | Cell death discovery | 2026 | name in title: sotorasib |
| PMID 41808249 | Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. | Cancer research communications | 2026 | name in abstract: sotorasib |
| PMID 41815506 | MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition. | JTO clinical and research reports | 2026 | name in title: sotorasib |
| PMID 41822354 | Tumor microenvironment-activated ferritin nanovector enables enhanced tumor delivery of KRASG12C inhibitors and degraders. | Frontiers in cell and developmental biology | 2026 | name in abstract: sotorasib |
| PMID 41830517 | MRTX1133 suppresses ERK signaling but elicits context-dependent antiproliferative responses in KRAS (G12C) cancer cells. | Molecular cancer therapeutics | 2026 | name in abstract: sotorasib |
| PMID 41839684 | Dual targeting of IGF-1R and K-RAS with natural phytochemicals for lung cancer therapy: an in-silico study. | Journal, genetic engineering & biotechnology | 2026 | name in abstract: sotorasib |
| PMID 41856615 | [Clinical characteristics of 20 lung adenocarcinoma patients misdiagnosed as interstitial pneumonia]. | Zhonghua yi xue za zhi | 2026 | name in abstract: sotorasib |
| PMID 41888140 | Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations. | Nature communications | 2026 | name in abstract: sotorasib |
| PMID 41898563 | MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy. | International journal of molecular sciences | 2026 | name in abstract: sotorasib |
| PMID 41915587 | Advancements in Sotorasib: A Comprehensive Review of its Efficacy in Non-small Lung Cancer Treatment. | Recent patents on anti-cancer drug discovery | 2026 | name in title: sotorasib |
| PMID 41998662 | MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis. | Respiratory research | 2026 | name in abstract: sotorasib |
| PMID 42002901 | Immunohistochemical Localization of Sotorasib-Protein Conjugates in the Rat Gastrointestinal Tract. | Biological & pharmaceutical bulletin | 2026 | name in title: sotorasib |
| PMID 42003513 | Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer. | Expert opinion on drug discovery | 2026 | name in abstract: sotorasib |
| PMID 42006282 | Sotorasib in Advanced KRAS G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS Metastases. | JTO clinical and research reports | 2026 | name in title: sotorasib |
| PMID 42007639 | Galangin Overcomes Gefitinib and Sotorasib Resistance in Non-small Cell Lung Cancer by Inhibiting Efferocytosis. | Journal of agricultural and food chemistry | 2026 | name in title: sotorasib |
| PMID 42007988 | ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window. | Molecular cancer therapeutics | 2026 | name in abstract: sotorasib |
| PMID 42031346 | From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC. | Critical reviews in oncology/hematology | 2026 | name in abstract: sotorasib |
| PMID 42031711 | AURKA/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant NSCLC. | Cell death discovery | 2026 | name in abstract: sotorasib |
| PMID 42034368 | Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan. | Respiratory investigation | 2026 | name in abstract: sotorasib |
| PMID 42041157 | MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells. | Molecular cancer therapeutics | 2026 | name in abstract: sotorasib |
| PMID 42055521 | KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status. | Cancer treatment and research communications | 2026 | name in abstract: sotorasib |
| PMID 42056373 | Bioinformatics and computational exploration of novel inhibitors targeting KRAS G12C mutant protein in lung adenocarcinoma. | Discover oncology | 2026 | name in abstract: sotorasib |
| PMID 42077604 | Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond. | Therapeutic advances in medical oncology | 2026 | name in abstract: sotorasib |
| PMID 42090290 | Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis. | Cell reports | 2026 | name in title: sotorasib |
| PMID 42090632 | Targeting KRAS G12C in Rare Mesonephric Carcinoma of the Cervix: A Promising Response to Sotorasib. | JCO precision oncology | 2026 | name in title: sotorasib |
| PMID 42094443 | Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition. | bioRxiv : the preprint server for biology | 2026 | name in abstract: sotorasib |
| PMID 42098425 | Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases. | Journal of neuro-oncology | 2026 | name in abstract: sotorasib |
| PMID 42099550 | Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with sotorasib. | The journal of liquid biopsy | 2026 | name in title: sotorasib |
| PMID 42114275 | KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians. | Cancer treatment reviews | 2026 | name in abstract: sotorasib |
| PMID 42122163 | Discovery of Structurally Distinct Covalent KRAS G12C Inhibitor Scaffolds Through Large-Scale In Silico Screening and Experimental Validation. | Cancers | 2026 | name in abstract: sotorasib |
| PMID 42124568 | mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion. | bioRxiv : the preprint server for biology | 2026 | name in abstract: sotorasib |
| PMID 42144204 | Sotorasib induces intestinal epithelial injury through suppression of the cAMP/PKA/CREB signaling axis. | Biochemical pharmacology | 2026 | name in title: sotorasib |
| PMID 42170277 | Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRASG12C -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors. | Translational lung cancer research | 2026 | name in title: sotorasib |
| PMID 42187721 | Disrupting the Undruggable: Emerging Modalities for Targeting Protein-Protein Interactions in Oncology. | Biology | 2026 | name in abstract: AMG 510 |
| PMID 42190605 | Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms. | Translational oncology | 2026 | name in title: sotorasib |
| PMID 42224643 | Standard Versus Reduced Sotorasib Dosing in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis-Have We Answered the Dosing Question? | JCO oncology practice | 2026 | name in title: sotorasib |
| PMID 42229337 | Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England. | Lung cancer (Amsterdam, Netherlands) | 2026 | name in title: sotorasib |
| PMID 42279426 | Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance. | Cancers | 2026 | name in abstract: sotorasib |
| PMID 42282123 | Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases. | Journal of the National Cancer Center | 2026 | name in abstract: AMG 510 |
| PMID 42283833 | Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies. | Naunyn-Schmiedeberg's archives of pharmacology | 2026 | name in abstract: sotorasib |
| PMID 42294187 | Machine Learning-Driven Drug Repurposing for KRAS G12C and KRAS G12D Inhibition. | ACS omega | 2026 | name in abstract: sotorasib |
| PMID 42336204 | Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2026 | name in abstract: sotorasib |
| PMID 42386216 | Targeting KRAS for cancer therapy. | British journal of pharmacology | 2026 | name in abstract: sotorasib |
| PMID 42393288 | Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. | Oncogene | 2026 | name in abstract: sotorasib |
| PMID 42415848 | M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS. | bioRxiv : the preprint server for biology | 2026 | name in abstract: sotorasib |
| PMID 42446418 | Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors. | Journal of medicinal chemistry | 2026 | name in abstract: sotorasib |
| PMID 42448954 | KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion. | Apoptosis : an international journal on programmed cell death | 2026 | name in abstract: sotorasib |
| PMID 42450070 | Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies. | International journal of molecular sciences | 2026 | name in abstract: sotorasib |
| PMID 42511798 | KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. | International journal of molecular sciences | 2026 | name in abstract: sotorasib |
| PMID 42514855 | RAS Inhibitors: Changing the Paradigm from the Undruggable. | Pharmaceutics | 2026 | name in abstract: sotorasib |
| PMID 42536138 | Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and carbon ions irradiation. | Molecular and cellular biochemistry | 2026 | name in abstract: sotorasib |
| PMID 42551924 | [Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: sotorasib |
| PMID 42551925 | [Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: sotorasib |
| PMID 42551926 | [Targeting KRAS-Mutant Cancers-Therapeutic Strategies and Mechanisms of Resistance to RAS Inhibitors]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: sotorasib |
| PMID 42557306 | M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors. | Oncogene | 2026 | name in abstract: sotorasib |
| PMID 42593915 | Property-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor. | Journal of medicinal chemistry | 2026 | name in abstract: sotorasib |
| PMID 42607542 | Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft. | Neoplasia (New York, N.Y.) | 2026 | name in title: sotorasib |
| PMID 42611092 | KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions. | Journal of gastrointestinal cancer | 2026 | name in abstract: sotorasib |
| PMID 42622884 | KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: sotorasib |
| PMID 42653726 | Development of a PK/PD-Efficacy Modeling Framework for Covalent Inhibitors. | Pharmaceuticals (Basel, Switzerland) | 2026 | name in abstract: sotorasib |
| PMID 42688109 | Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies. | Frontiers in oncology | 2026 | name in abstract: sotorasib |
| PMID 42699034 | Theoretical study of KRAS G12C secondary mutations influencing inhibitor resistance. | Biophysics and physicobiology | 2026 | name in abstract: sotorasib |
| PMID 42703145 | Sotorasib and Panitumumab: A breakthrough in the treatment of KRAS-mutated mCRC. | JPMA. The Journal of the Pakistan Medical Association | 2026 | name in title: sotorasib |
| PMID 42707601 | KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies. | Frontiers in oncology | 2026 | name in abstract: sotorasib |
| PMID 42716336 | An Application of Iterative Health Economic Evaluation: An Update on the Early Cost Effectiveness of Whole Genome Sequencing in Advanced Non-small Cell Lung Cancer. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2026 | name in abstract: sotorasib |
| PMID 42720810 | Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: sotorasib |
| PMID 42726935 | KRAS-G12C inhibition-induced enrichment of MHC-Ihigh immune-active tumor cells directs immune-effector TME development to augment therapeutic efficacy. | Cancer immunology research | 2026 | name in abstract: sotorasib |
| PMID 42749446 | Computational identification and characterization of high-risk human KRAS nsSNPs: Impacting structure, ligand binding, and cancer prognosis. | Journal, genetic engineering & biotechnology | 2026 | name in abstract: sotorasib |
| PMID 42759542 | Targeting KRAS-Mutant Lung Cancers. | Journal of the National Comprehensive Cancer Network : JNCCN | 2026 | name in abstract: sotorasib |
| PMID 42771901 | Real-world Experience with Sotorasib in KRAS G12C-Mutated Advanced Non-small Cell Lung Cancer: Clinical Outcomes and Tolerability in the UK. | Clinical oncology (Royal College of Radiologists (Great Britain)) | 2026 | name in title: sotorasib |
| PMID 42860233 | Blockade of mutant RAS oncogenic signaling: A 2026 update. | Pharmacological research | 2026 | name in abstract: sotorasib |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| F30CA281272 | Maximizing Selective Inhibition of Clinically Observed MET Mutants | STATE UNIVERSITY NEW YORK STONY BROOK | OUTHWAITE, IAN | 2024–2026 | name in abstract: sotorasib |
| K01CA313805 | Targeting a novel covalent RAS dimer in RASQ61 mutants-driven cancers | UT SOUTHWESTERN MEDICAL CENTER | ZHOU, ZHIWEI | 2026–2026 | name in abstract: sotorasib |
| K22CA276357 | Targeted degradation of KRAS oncoproteins triggers antitumor immunity and abolishes lung tumor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | ZHANG, HUA | 2024–2026 | name in abstract: sotorasib |
| P30CA016672 | Stem Cell Biology & Cellular Therapy Program | UNIVERSITY OF TX MD ANDERSON CAN CTR | SHPALL, ELIZABETH J | 2019–2026 | name in abstract: sotorasib |
| R01CA131261 | Studying the initiation, progression and therapy of lung cancer in mouse models | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH | MCMAHON, MARTIN | 2023–2026 | name in abstract: sotorasib |
| R01CA270240 | Proteostasis Reprogramming in Mutant KRAS-Driven Cancers | UNIVERSITY OF TX MD ANDERSON CAN CTR | CHEN, XI | 2023–2026 | name in abstract: sotorasib |
| R01CA279194 | Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC. | UNIVERSITY OF TX MD ANDERSON CAN CTR | SKOULIDIS, FERDINANDOS | 2023–2026 | name in abstract: sotorasib |
| R01CA279264 | Mechanisms of adaptation and resistance to emerging therapies for lung cancer | SLOAN-KETTERING INST CAN RESEARCH | LITO, PIRO | 2023–2026 | name in abstract: sotorasib |
| R01CA281295 | KRAS G12C: Kinetic and Redox Characterization of Covalent Inhibition | UNIV OF NORTH CAROLINA CHAPEL HILL | CAMPBELL, SHARON L | 2023–2026 | name in abstract: sotorasib |
| R01CA283049 | Novel approaches to target KEAP1 mutant tumors | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | PAPAGIANNAKOPOULOS, THALES | 2024–2026 | name in abstract: sotorasib |
| R01CA285743 | Synthetic lethal targeting of KRAS/KEAP1 co-mutant non-small cell lung cancer | RUSH UNIVERSITY MEDICAL CENTER | MAKI, CARL G | 2024–2026 | name in abstract: sotorasib |
| R01CA285926 | Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancer | MEDICAL UNIVERSITY OF SOUTH CAROLINA | OGRETMEN, BESIM | 2024–2026 | name in abstract: sotorasib |
| R01CA296154 | Highly tumor-selective pan RAS inactivators for targeting oncogenic RAS-driven cancers | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | LIU, SHIHUI | 2025–2026 | name in abstract: sotorasib |
| R01CA311659 | Covalent Inhibitors of Ras Q61 Mutations in Cancer | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | HUANG, BENJAMIN | 2026–2026 | name in abstract: sotorasib |
| R21CA295906 | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors | UNIVERSITY OF TX MD ANDERSON CAN CTR | LISSANU, YONATHAN | 2025–2026 | name in abstract: sotorasib |
| R21CA296712 | Proximity-triggered, mutant-specific modification of K-Ras(G12C) with local polypharmaceutical release | COLD SPRING HARBOR LABORATORY | MOSES, JOHN EDWARD | 2025–2026 | name in abstract: sotorasib |
| R35GM124637 | MIRA: Atropisomerism as an inspiration for drug discovery and new chemistry | STATE UNIVERSITY NEW YORK STONY BROOK | GUSTAFSON, JEFFREY LOUIS | 2022–2026 | name in abstract: AMG 510 |
| U54CA224083 | Research Project 2 | WASHINGTON UNIVERSITY | LIM, KIAN-HUAT | 2023–2026 | name in abstract: sotorasib |
| K22CA276632 | Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer | UNIVERSITY OF CINCINNATI | WATERS, ANDREW M | 2023–2025 | name in abstract: sotorasib |
| R01CA262469 | Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer | UNIVERSITY OF TX MD ANDERSON CAN CTR | SKOULIDIS, FERDINANDOS | 2021–2025 | name in abstract: AMG 510 |
| R21CA280163 | Expanding the targetable landscape in cancer with serine-targeting covalent ligands | UNIVERSITY OF CALIFORNIA BERKELEY | ZHANG, ZIYANG | 2024–2025 | name in abstract: sotorasib |
| R21CA286372 | The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung Cancer | UNIVERSITY OF MICHIGAN AT ANN ARBOR | GALBAN, STEFANIE | 2024–2025 | name in abstract: sotorasib |
| R21CA297690 | Noncovalent interaction of mutant KRAS inhibitors | DUKE UNIVERSITY | CHI, JEN-TSAN ASHLEY | 2025–2025 | name in abstract: sotorasib |
| R21CA302807 | Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancer | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | NEEL, BENJAMIN G. | 2025–2025 | name in abstract: sotorasib |
| R44AI177220 | Mitigation of Radiation Induced Gastrointestinal Syndrome. | BCN BIOSCIENCES, LLC | NORRIS, ANDREW JOHN | 2023–2025 | name in abstract: sotorasib |
| ZIABC011892 | Targeting RAS in Pediatric Cancer | DIVISION OF BASIC SCIENCES - NCI | YOHE, MARIELLE | 2019–2025 | name in abstract: sotorasib |
| ZIASC006321 | Modulation of Therapeutic Response | DIVISION OF CLINICAL SCIENCES - NCI | MITCHELL, JAMES | 2024–2025 | name in abstract: AMG 510 |
| F31CA261061 | Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC | WEILL MEDICAL COLL OF CORNELL UNIV | DIAZ, BIANCA | 2021–2024 | name in abstract: AMG 510 |
| F31CA261116 | Investigating KRAS Signaling and Autophagy Co-inhibition in KRAS-mutant Lung Cancer | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH | GHAZI, PHAEDRA | 2022–2024 | name in abstract: sotorasib |
| R37CA215427 | Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer | WAYNE STATE UNIVERSITY | AZMI, ASFAR S | 2023–2024 | name in abstract: sotorasib |
| R42CA275425 | Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent | PACDNA LLC | ZHANG, KE | 2022–2024 | name in abstract: sotorasib |
| R21CA267412 | Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers | UNIVERSITY OF MICHIGAN AT ANN ARBOR | LEOPOLD, JUDITH S | 2022–2023 | name in abstract: AMG 510 |
| R21CA282568 | Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approach | H. LEE MOFFITT CANCER CTR & RES INST | HAURA, ERIC B. | 2023–2023 | name in abstract: sotorasib |
| F32CA250231 | Targeting MCL-1 dependent apoptotic vulnerability of KRAS-LKB1 NSCLC | MASSACHUSETTS GENERAL HOSPITAL | LI, CHENDI | 2020–2022 | name in abstract: AMG 510 |
| U54CA233306 | Preclinical studies of KRAS and EGFR mutations in lung cancer PDXs | UNIVERSITY OF CALIFORNIA AT DAVIS | CARVAJAL CARMONA, LUIS GUILLERMO | 2022–2022 | name in abstract: sotorasib |
| R21CA252430 | Evaluating a Novel Autophagy Inhibitor in KRAS-Driven Lung Cancer | MICHIGAN STATE UNIVERSITY | MACKEIGAN, JEFFREY PAUL | 2021–2021 | name in abstract: AMG 510 |
Notes
KRAS G12C (OFF-state covalent). Approved (US 2021 Lumakras; EU Lumykras).
How to cite
sotorasib (AXP000023.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000023.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.